Ozempic (semaglutide): the 2026 buyer's guide
Ozempic is Novo Nordisk's once-weekly semaglutide injection, FDA-approved in 2017 for type 2 diabetes. Ozempic and Wegovy are the same active molecule (semaglutide); the difference is approved indication and maximum dose. Ozempic has been the most-prescribed off-label weight loss drug in the US since 2021. Below: how it differs from Wegovy, what trials show on weight loss as a secondary endpoint, 2026 pricing and which programs prescribe it.
Compare Ozempic prices →- Ozempic is a weekly injection of semaglutide, FDA-approved for type 2 diabetes since 2017.
- In the SUSTAIN-6 trial, mean weight loss was 5% over 104 weeks.
- It carries the GLP-1 class boxed warning for thyroid C-cell tumor risk, and is not for people with a personal or family history of medullary thyroid carcinoma or MEN2.
- Cash, insurance and compounded prices differ widely. See the cost breakdown below, and the all-in program costs on the chart.
What Ozempic costs in 2026
There is no one price. What you pay depends on which path you take:
Telehealth programs add a membership fee on top of the medication cost (typically $40-$200/mo). For all-in monthly costs by program, see the chart, the full GLP-1 cost guide, or calculate your exact all-in cost by drug, coverage and state.
For every cash path to Ozempic without insurance, the $998 retail list price, the NovoCare cash routes and the $178 compounded semaglutide alternative, see the Ozempic cost guide.
Who it's for
Adults with type 2 diabetes, as an adjunct to diet and exercise. Frequently prescribed off-label for weight loss in patients without diabetes; this is at the prescriber's discretion and may not be covered by insurance for the off-label use.
What the trials show
Ozempic's registration trial was SUSTAIN-6 (NEJM, 2016). At 104 weeks at the 1.0mg dose tested, mean weight loss was 5% (4.4 percentage points greater than placebo). SUSTAIN-6 is a cardiovascular-outcomes trial, not a weight-loss trial. It reports mean weight change at the 1.0mg dose as a secondary measure (about 4.9 kg lost versus 0.5 kg on placebo), but it does not report the share of patients losing 5% or 15% of body weight. Real-world results vary; trial patients are typically more adherent and more closely managed than typical telehealth patients.
Dose schedule
Dose levels: 0.25mg, 0.5mg, 1.0mg, 2.0mg. Standard practice is to titrate up monthly, holding at any tolerated dose. Maximum dose is 2.0mg weekly; many patients reach goal weight at sub-maximum doses and stay there.
Common side effects
The most commonly reported side effects in the registration trial:
- nausea (20%)
- diarrhea (12%)
- vomiting (9%)
- constipation (5%)
- abdominal pain (5%)
Boxed warning: Risk of thyroid C-cell tumors (rodent data); contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
How Ozempic differs from related drugs
Same molecule as Wegovy. Approved for diabetes, not weight loss. Maximum dose (2.0mg) is lower than Wegovy's (2.4mg). Insurance typically covers Ozempic only for diabetes; off-label weight loss patients usually pay cash or switch to Wegovy via prior authorization.
Compounded semaglutide
Compounded semaglutide is the same active molecule prepared by a 503A pharmacy under prescription rather than manufactured under FDA new-drug approval as Ozempic. Cash-pay savings versus branded Ozempic are typically 50-80%. The regulatory environment has tightened. FDA shortage list resolved October 2024; off-label prescribing for weight loss continues but insurance coverage for off-label use is rare in 2026. For the comparison, see compounded vs FDA-approved semaglutide.
Programs that prescribe Ozempic
These programs in our chart prescribe Ozempic (with insurance coverage where applicable, or as a cash-pay option). Ranked by overall score.
Some visit links earn us a commission.
Ozempic vs other GLP-1s
Learn more about Ozempic
References
- SUSTAIN-6 registration trial. New England Journal of Medicine, 2016.
- Ozempic FDA prescribing information (DailyMed).
Trial figures are mean results at the maximum dose in the cited registration trial. Real-world outcomes vary with adherence and clinical management.
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Talk to a licensed clinician about whether Ozempic is appropriate for you. Pricing reflects publicly verified rates as of June 22; verify with the manufacturer or your prescriber before committing.
